Kyverna Therapeutics, Inc.
KYTX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$5.39
KIRA · Stoqly’s AI analyst, in plain words
- Kyverna Therapeutics, Inc. lost $161M in fiscal 2025.
- Free cash flow was −$154M in fiscal 2025, — of revenue.
- Kyverna Therapeutics, Inc. has $254M more cash than debt.
Market cap
$328M
P/E
—
Revenue
—
Net income
−$161M
Free cash flow
−$154M
Operating margin
—
Kyverna Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$161M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kyverna Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Kyverna Therapeutics, Inc.
- CIK
- 0001994702
Kyverna Therapeutics, Inc. · KYTX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$60.4M | −$127M | −$161M |
| Diluted EPS | −$89.61 | −$3.33 | −$3.64 |
| Cash | |||
| Cash from operations | −$52.4M | −$114M | −$154M |
| Capital expenditure | $0.6M | $2.2M | $0.0M |
| Free cash flow | −$53.0M | −$116M | −$154M |
| Share count change | — | 5,591.0% | 15.5% |
| Debt and strength | |||
| Cash and short-term investments | $57.5M | $286M | $279M |
| Debt incl. finance leases | — | — | $25.1M |
| Shareholders' equity | −$13.1M | $267M | $232M |
| Current ratio | 3.1x | 8.6x | 7.8x |
| Interest coverage | −333.7x | −1,004.3x | −347.3x |
| Returns and quality | |||
| Return on equity | — | −100.6% | −64.7% |
| Return on tangible equity | — | −47.8% | −69.4% |
| Altman Z'' | −8.4 | 6.9 | 0.9 |
Insiders bought, 12 months
$2.0M
2 insiders
Insiders sold, 12 months
$0.3M
1 insider
Of sales under plans
100%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kyverna Therapeutics, Inc. · KYTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.39 a share, the company is worth $328M.
Source: SEC EDGAR XBRL filings (CIK 0001994702). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.